Minerva’s Shares Surge 166% as Seltorexant Deal Fuels Phase 3 Rolupe Trials

Introduction

Minerva Neurosciences Inc (NASDAQ: NERV) is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The firm is focused on developing therapies for disorders of the central nervous system (CNS), with a pipeline that includes roluperidone (MIN-101) for negative symptoms of schizophrenia and MIN-301 in pre-clinical development for Parkinson’s disease.

Corporate Structure and Management

While Minerva does not disclose total headcount publicly, its executive leadership has extensive experience in CNS and pharmaceutical development:

• Dr. Remy Luthringer, Executive Chairman & CEO since November 2014, holds a PhD in neurosciences and clinical pharmacology and has overseen the development of over 150 clinical trial molecules.
• Geoff Race, President and Chief Business Officer, co-founded the company and has led finance and business development since 2014; he holds an MBA from Durham University.
• Dr. Michael Davidson, Chief Medical Officer, has published over 300 articles in schizophrenia and Alzheimer’s research and received neuroscience awards from the European College of Neuropsychopharmacology (ECNP) and the International College of Neuropsychopharmacology (ICNP).
• Fred Ahlholm, Chief Financial Officer since May 2015, is a CPA with previous roles at Amarin Corporation.
• Joe Reilly, Senior VP & COO, has over a decade of experience in commercial operations from Genzyme.
• Dr. Jay Saoud, CNS trial consultant, has contributed to the development of more than 125 active molecules and 11 New Drug Applications (NDAs).

CNS therapies by Annie Spratt

Recent Developments and News

• January 19, 2021: Royalty Pharma acquired Minerva’s royalty interest in seltorexant (a Phase 3 antidepressant candidate) for an upfront payment of $60 million and up to $95 million in milestone payments. Proceeds are intended to fund roluperidone’s Phase 3 program.
• March 17, 2025: Minerva regained compliance with Nasdaq Listing Rule 5550(b)(3), allowing for continued listing on the Nasdaq Capital Market.
• May 13, 2025: First-quarter financial results for the period ended March 31, 2025:
  • R&D expense of $1.4 million (down from $4.2 million in Q1 2024)
  • G&A expense of $2.5 million (unchanged year-over-year)
  • Net loss of $3.8 million, or $0.50 per share (compared to a $8.6 million net loss, or $1.13 per share, in Q1 2024)
  • Cash, cash equivalents, and restricted cash of $17.4 million (down from $21.5 million at December 31, 2024)

As of October 21, 2025, NERV shares closed at $7.08, reflecting an increase of 166.17%, on a volume of 16,532,507 shares, indicating a market capitalization of approximately $49 million.

Financial and Strategic Analysis

Minerva’s Q1 2025 R&D spending decreased as costs associated with the NDA review for roluperidone and a Phase 2 C18 study approached completion. The sale of seltorexant royalties provided non-dilutive capital to support Phase 3 roluperidone trials. With a quarterly loss of approximately $3.8 million and $17.4 million in cash, the company’s financial position supports operations into late 2025, assuming consistent operating expenses. Upcoming milestones include interactions with the FDA regarding the Complete Response Letter on roluperidone’s NDA and potential partnership or financing arrangements for the MIN-301 program.

Market Position and Industry Context

Minerva operates in the competitive CNS specialty sector, where there are unmet needs in managing negative symptoms of schizophrenia and Parkinson’s disease. The company designs clinical trials with endpoints directly related to patient benefits and seeks to recruit suitable patient populations. Collaborative agreements—such as the arrangement with Royalty Pharma regarding seltorexant and development partnership with Janssen Pharmaceutica—demonstrate Minerva’s strategy of leveraging external expertise and funding to advance its late-stage assets.

tl;dr

• On October 21, 2025, NERV shares rose to $7.08 (+166%), with trading volume of 16.5 million.
• Q1 2025 net loss was reported at $3.8 million; cash position was $17.4 million as of March 31, 2025.
• Royalty Pharma’s January 2021 acquisition of seltorexant royalties is designated to fund Phase 3 studies of roluperidone.
• Ongoing FDA discussions are aimed at addressing the Complete Response Letter for roluperidone’s NDA.
• Cash runway is expected to extend into late 2025; key upcoming milestones include FDA feedback and potential financing for MIN-301.